Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

465
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
Time Course of Drug Effect01:14

Time Course of Drug Effect

3.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
3.0K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

333
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
333
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Modern diagnostic and treatment approach for colonic diverticulitis in the Russian Federation: survey of specialists].

Khirurgiiaยท2026
Same author

[Validation of the Russian version of the Carolinas Comfort Scale in patients after previous abdominal hernia repair with mesh].

Khirurgiiaยท2025
Same author

[Long-term outcomes of laparoscopic inguinal hernia repair].

Khirurgiiaยท2024
Same author

[WAYS TO SOLVE THE PROBLEM OF HOME PARENTERAL NUTRITION IN PATIENTS WITH SHORT BOWEL SYNDROME].

Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsinyยท2022
Same author

[Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy].

Terapevticheskii arkhivยท2022
Same author

Physiological Media in Studies of Cell Metabolism.

Molecular biologyยท2022
Same journal

Stenting of the colon in surgery of colorectal cancer complicated by intestinal obstruction.

Vestnik khirurgii imeni I. I. Grekovaยท2018
Same journal

Modern strategy in treatment of esophageal cancer.

Vestnik khirurgii imeni I. I. Grekovaยท2018
Same journal

Theoretical and practical aspects in application of hypothermia in thoracic aorta surgery.

Vestnik khirurgii imeni I. I. Grekovaยท2018
Same journal

Diagnostic and treatment problems of brain abscesses.

Vestnik khirurgii imeni I. I. Grekovaยท2018
Same journal

SURGICAL SAFETY CHECKLIST: FROM IDEA TO PRACTICAL APPLICATION.

Vestnik khirurgii imeni I. I. Grekovaยท2018
Same journal

Diagnostics and treatment of venous mesenteric venous thrombosis.

Vestnik khirurgii imeni I. I. Grekovaยท2018
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

[CHANGE OF ANTICOAGULANT EFFECT OF RIVAROXABAN DURING A DAY].

I V Gel'tser, O A Smirnova, O Yu Matvienko

    Vestnik Khirurgii Imeni I. I. Grekova
    |November 26, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Rivaroxaban demonstrated a significant anticoagulant effect in patients with thromboembolic diseases, enhancing the protein C system

    More Related Videos

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    18.1K
    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K

    Related Experiment Videos

    Last Updated: Mar 29, 2026

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
    11:17

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

    Published on: October 12, 2012

    14.5K
    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    18.1K
    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K

    Area of Science:

    • Pharmacology
    • Hematology
    • Thrombosis Research

    Context:

    • Assessing the anticoagulant properties of novel oral anticoagulants.
    • Understanding the mechanisms of action for rivaroxaban.
    • Evaluating treatment efficacy in thromboembolic disease management.

    Purpose:

    • To evaluate the anticoagulant effect of rivaroxaban.
    • To investigate the impact of rivaroxaban on the protein C system.
    • To assess the duration of rivaroxaban's anticoagulant activity.

    Summary:

    • Rivaroxaban exhibited a pronounced anticoagulant effect in 35 patients with thromboembolic diseases.
    • The anticoagulant effect persisted for at least 24 hours.
    • Increased sensitivity to thrombomodulin suggested enhanced protein C system activity during rivaroxaban therapy.

    Impact:

    • Provides insights into rivaroxaban's clinical efficacy.
    • Highlights the role of the protein C system in rivaroxaban's mechanism.
    • Informs therapeutic strategies for thromboembolic disorders.